Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sana Biotechnology, Inc. - Common Stock (NQ:SANA)

2.555 +0.115 (+4.71%)
Delayed Quote Updated: 11:56 AM EST, Nov 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sana Biotechnology, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Sana Biotechnology Publishes Early Clinical Data Showing that SC291, a CD19-directed Allogeneic CAR T Therapy, Evades Immune Detection in Presence of Intact Immune System
From Sana Biotechnology, Inc
Via GlobeNewswire
News headline image
Sana Biotechnology to Present at November and December 2023 Investor Conferences
From Sana Biotechnology, Inc
Via GlobeNewswire
News headline image
Uppsala University Hospital and Sana Biotechnology Announce Authorization of the First-in-Human Clinical Trial Application for a Primary Islet Cell Treatment for Patients with Type 1 Diabetes
From Sana Biotechnology, Inc
Via GlobeNewswire
News headline image
Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-directed Allogeneic CAR T Therapy, for Patients with Lupus Nephritis, Extrarenal Lupus, and ANCA-associated Vasculitis
From Sana Biotechnology, Inc
Via GlobeNewswire
News headline image
Sana Biotechnology Reports Third Quarter 2023 Financial Results and Business Updates
From Sana Biotechnology, Inc
Via GlobeNewswire
News headline image
Sana Biotechnology Announces Five Presentations at the 65th American Society of Hematology Annual Meeting
From Sana Biotechnology, Inc
Via GlobeNewswire
News headline image
Sana Biotechnology Announces Increased Focus on Hypoimmune-Related Pipeline with the Potential to Deliver Clinical Proof of Concept Data from Four Programs in 2023 and 2024 with a 2024 Operating Burn under $200M
From Sana Biotechnology, Inc
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 25, 2023 ↗
 
Via Benzinga
News headline image
Why Eiger BioPharmaceuticals Shares Are Trading Lower By 52%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Avalo Therapeutics, Inc. (NASDAQ: AVTX) shares surged 68% to $0.2075. Avalo Therapeutics, on Sept 12, got notice from the Nasdaq as of Sept 11 the company’s securities had closing bid price of... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Sana Biotechnology to Present at September 2023 Investor Conferences
From Sana Biotechnology, Inc
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 5, 2023 ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 14, 2023 ↗
 
Via Benzinga
News headline image
Sana Biotechnology Reports Second Quarter 2023 Financial Results and Business Updates
From Sana Biotechnology, Inc
Via GlobeNewswire
News headline image
3 Hidden Penny Stocks That Could Turn $100 into $10,000 ↗
These penny stocks have multibagger upside potential with great margins of safety, according to Wall Street analysts. 
Via InvestorPlace
News headline image
Sana Biotechnology Highlights Preclinical Data from Hypoimmune and Fusogen Platforms at the International Society for Stem Cell Research (ISSCR) 2023 Annual Meeting
From Sana Biotechnology, Inc
Via GlobeNewswire
News headline image
Sana Biotechnology to Present at June 2023 Investor Conferences
From Sana Biotechnology, Inc
Via GlobeNewswire
News headline image
Why Nvidia Shares Are Trading Higher By Over 5%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers QualTek Services Inc. (NASDAQ: QTEK) shares jumped 127.2% to $0.1740 after dropping around 21% on Friday. Qualtek Services recently filed voluntarily petitions for Chapter 11 bankruptcy. 
Via Benzinga
News headline image
Skyline Champion, Atea Pharmaceuticals And Other Big Stocks Moving Lower On Tuesday ↗
U.S. stocks traded mixed, with the Dow Jones dropping over 100 points on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
News headline image
Why Venus Concept Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Gainers NeoGames S.A. (NASDAQ: NGMS) shares climbed 113.3% to $27.38 as the company agreed to be acquired by Aristocrat Leisure Limited for $29.50 per share in cash. 
Via Benzinga
News headline image
Sana Biotechnology Announces Preclinical Data Published in Nature Biotechnology Demonstrating its Hypoimmune-Engineered Cells Escape Immune Detection and Survive While Remaining Fully Functional
From Sana Biotechnology, Inc
Via GlobeNewswire
News headline image
Sana Biotechnology Reports First Quarter 2023 Financial Results and Business Updates
From Sana Biotechnology, Inc
Via GlobeNewswire
News headline image
7 High-Potential Penny Stocks in the Biotech Sector ↗
Most of the biggest biotech stocks on the market started off as unknown penny stocks. Here are seven hot ones to consider. 
Via InvestorPlace
News headline image
Sana Biotechnology to Present at May 2023 Investor Conferences
From Sana Biotechnology, Inc
Via GlobeNewswire
News headline image
Sana Biotechnology Announces the Acceptance of Six Abstracts for Presentation at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting
From Sana Biotechnology, Inc
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 2, 2023 ↗
 
Via Benzinga
News headline image
Sana Biotechnology to Host Research & Development Day
From Sana Biotechnology, Inc
Via GlobeNewswire
News headline image
The Top 3 Biotech Stocks to Watch in 2023 ↗
Investors would be wise to keep an eye on the biotech boom, and these top biotech stocks to watch as we get deeper into 2023. 
Via InvestorPlace
News headline image
Sana Biotechnology Highlights Preclinical Hypoimmune Data for its Allogeneic CAR T Platform and Advancements with its In Vivo Fusogen Platform with Four Presentations at the 2023 AACR Annual Meeting
From Sana Biotechnology, Inc
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.